Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men

Metabolism ◽  
2002 ◽  
Vol 51 (4) ◽  
pp. 531-536 ◽  
Author(s):  
Bernd Fruehwald-Schultes ◽  
Kerstin M. Oltmanns ◽  
Barbara Toschek ◽  
Stefan Sopke ◽  
Werner Kern ◽  
...  
Keyword(s):  
Body Weight ◽  
Body Fat ◽  
Fat Content ◽  
Term Treatment ◽  
Normal Weight ◽  
Short Term ◽  
Short Term Treatment ◽  
Serum Leptin ◽  
Healthy Men ◽  
Body Fat Content

Estimation of body fat content from standard body length and body weight on cultured red sea bream

2000 ◽  
Vol 66 (2) ◽  
pp. 365-371 ◽  
Author(s):  
H ARUE KORA ◽  
M UTSUYOSI TSUCHIMOTO ◽  
K ATSUYA MIYATA ◽  
S HINKO OSATO ◽  
Q IN WANG ◽  
...  
Keyword(s):  
Body Weight ◽  
Body Length ◽  
Red Sea ◽  
Body Fat ◽  
Fat Content ◽  
Sea Bream ◽  
Red Sea Bream ◽  
Body Fat Content

Body Composition in Adolescents and Young Adults with Anorexia Nervosa: A Clinical Review

2020 ◽  
Vol 16 (2) ◽  
pp. 92-98 ◽  
Author(s):  
Hana Tannir ◽  
Leila Itani ◽  
Dima Kreidieh ◽  
Dana El Masri ◽  
Samira Traboulsi ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Body Composition ◽  
Body Weight ◽  
Anorexia Nervosa ◽  
Body Fat ◽  
Weight Maintenance ◽  
Normal Weight ◽  
Mineral Density ◽  
Short Term ◽  
Weight Restoration

Background: Anorexia nervosa is a serious health condition characterized by a significant low body weight and alteration in body composition components. Aim: In the current paper, we aim to summarize the available literature concerning changes in body fat, lean, and bone masses, during anorexia nervosa and after complete weight restoration. Methods: Data were summarized using a narrative approach based on clinical expertise in the interpretation of the available evidence base in the literature. Results: The available data revealed three main findings. Firstly, anorexia nervosa causes a significant reduction in body fat mass, however it is completely restored after short-term weight normalization but with a central adiposity phenotype that does not seem to negatively influence treatment outcomes and appears to normalize after 1 year of normal weight maintenance. Secondly, anorexia nervosa causes a significant reduction in bone mineral density, but weight restoration is associated first (≈12 months) with stabilization of bone mineral density, followed by improvements (after ≈16 months); and finally, with complete normalization (after ≈30 months) after normal-weight maintenance. Thirdly, during anorexia nervosa loss of lean and skeletal body mass occurring in particular from the extremities rather than the central regions has been consistently reported, especially in patients with a Body Mass Index (BMI) ≤ 16.5 Kg/m2 however short-term weight restoration is associated with complete normalization. Conclusion: Anorexia nervosa adversely affects body composition, however this medical complication seems to be reversible through the main treatment strategy of body weight restoration followed by normal weight maintenance, and this should be openly discussed with patients.

scholarly journals Unchanged Testosterone Production Rates in Growth Hormone-Treated Healthy Men1

1998 ◽  
Vol 83 (10) ◽  
pp. 3735-3736
Author(s):  
H. Vierhapper ◽  
P. Nowotny ◽  
W. Waldhäusl
Keyword(s):  
Plasma Concentrations ◽  
Term Treatment ◽  
Dilution Technique ◽  
Production Rates ◽  
Short Term ◽  
Short Term Treatment ◽  
Healthy Men ◽  
Stable Isotope Dilution ◽  
Testosterone Production ◽  
Daily Dose

The effect of biosynthetic human GH on the production rates of testosterone was determined in healthy men (n = 7) using the stable isotope dilution technique and mass spectrometry. 1α,2α-d-Testosterone (20 μg/h) was infused for 10 h (0800–1800 h). Blood samples obtained at 20-min intervals from 1400–1800 h were pooled during two 2-h periods. Subsequently, each volunteer received a daily dose of biosynthetic human GH (4 IU/day sc) for 7 days. This resulted in a rise in plasma concentrations of somatomedin-C from, basal, 0.67 ± 0.13 U/mL to 1.20± 0.2 U/mL on day 7 (P < 0.0001). Testosterone production rates (basal: 209.9 ± 31.0 μg/h) were unchanged by treatment with GH (day 7: 192.2 ± 30.1 μg/h). In healthy men, short-term treatment with sc GH does not influence endogenous testosterone production rates.

Dissociation of Serum Leptin Concentration and Body Fat Content During Long Term Dietary Intervention in Obese Individuals

1996 ◽  
Vol 28 (12) ◽  
pp. 718-723 ◽  
Author(s):  
G. Scholz ◽  
P. Englaro ◽  
I. Thiele ◽  
M. Scholz ◽  
T. Klusmann ◽  
...  
Keyword(s):  
Body Fat ◽  
Dietary Intervention ◽  
Fat Content ◽  
Serum Leptin ◽  
Body Fat Content

scholarly journals Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets

2010 ◽  
Vol 162 (1) ◽  
pp. 75-83 ◽  
Author(s):  
Solrun Vidarsdottir ◽  
Ferdinand Roelfsema ◽  
Trea Streefland ◽  
Jens J Holst ◽  
Jens F Rehfeld ◽  
...  
Keyword(s):  
Weight Gain ◽  
Peptide Yy ◽  
Hormone Secretion ◽  
Gut Hormones ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Healthy Men ◽  
Gut Hormone ◽  
Glucagon Like Peptide 1

BackgroundTreatment with olanzapine (atypical antipsychotic drug) is frequently associated with various metabolic anomalies, including obesity, dyslipidemia, and diabetes mellitus. Recent data suggest that olanzapine orally disintegrating tablets (ODT), which dissolve instantaneously in the mouth, might cause less weight gain than olanzapine standard oral tablets (OST).Design and methodsTen healthy men received olanzapine ODT (10 mg o.d., 8 days), olanzapine OST (10 mg o.d., 8 days), or no intervention in a randomized crossover design. At breakfast and dinner, blood samples were taken for measurement of pancreatic polypeptide, peptide YY, glucagon-like peptide-1, total glucagon, total ghrelin, and cholecystokinin (CCK) concentrations.ResultsWith the exception of pre- and postprandial concentration of ghrelin at dinner and preprandial CCK concentrations at breakfast, which were all slightly increased (respectivelyP=0.048,P=0.034 andP=0.042), olanzapine did not affect gut hormone concentrations. Thus, olanzapine ODT and OST had similar effects on gut hormone secretion.ConclusionShort-term treatment with olanzapine does not have major impact on the plasma concentration of gut hormones we measured in healthy men. Moreover, despite pharmacological difference, gut hormone concentrations are similar during treatment with olanzapine ODT and OST. The capacity of olanzapine to induce weight gain and diabetes is unlikely to be caused by modulation of the secretion of gut hormones measured here. We cannot exclude the possibility that olanzapine's impact on other gut hormones, to impair insulin sensitivity and stimulate weight gain, exists.

Mice with experimental colitis show an altered metabolism with decreased metabolic rate

2007 ◽  
Vol 292 (1) ◽  
pp. G165-G172 ◽  
Author(s):  
Silvia Melgar ◽  
Mikael Bjursell ◽  
Anna-Karin Gerdin ◽  
Lennart Svensson ◽  
Erik Michaëlsson ◽  
...  
Keyword(s):  
Body Weight ◽  
Metabolic Rate ◽  
Chronic Inflammation ◽  
Body Fat ◽  
Experimental Colitis ◽  
Fat Content ◽  
The Body ◽  
Mineral Density ◽  
Metabolic Alterations ◽  
Body Fat Content

Patients with inflammatory bowel disease (IBD) suffer from body weight loss, malnutrition, and several other metabolic alterations affecting their quality of life. The aim of this study was to investigate the metabolic changes that may occur during acute and chronic colonic inflammation induced by dextran sulfate sodium (DSS) in mice. Clinical symptoms and inflammatory markers revealed the presence of an ongoing inflammatory response in the DSS-treated mice. Mice with acute inflammation had decreased body weight, respiratory exchange ratios (RER), food intake, and body fat content. Mice with chronic inflammation had decreased nutrient uptake, body fat content, locomotor activity, metabolic rates, and bone mineral density. Despite this, the body weight, food and water intake, lean mass, and RER of these mice returned to values similar to those in healthy controls. Thus, murine experimental colitis is associated with significant metabolic alterations similar to IBD patients. Our data show that the metabolic responses during acute and chronic inflammation are different, although the metabolic rate is reduced in both phases. These observations suggest compensatory metabolic alterations in chronic colitis resulting in a healthy appearance despite gross colon pathology.

scholarly journals High-calcium diet with whey protein attenuates body-weight gain in high-fat-fed C57Bl/6J mice

2007 ◽  
Vol 98 (5) ◽  
pp. 900-907 ◽  
Author(s):  
Taru K. Pilvi ◽  
Riitta Korpela ◽  
Minna Huttunen ◽  
Heikki Vapaatalo ◽  
Eero M. Mervaala
Keyword(s):  
Body Weight ◽  
Whey Protein ◽  
Body Fat ◽  
Fat Content ◽  
High Fat ◽  
Final Body Weight ◽  
High Calcium ◽  
Significant Difference ◽  
Body Fat Content ◽  
Fat Excretion

An inverse relationship between Ca intake and BMI has been found in several studies. It has been suggested that Ca affects adipocyte metabolism via suppressing 1,25-dihydroxycholecalciferol (1,25(OH)2-D3) and decreases fat absorption. We studied the effect of Ca and milk proteins (whey and casein) on body weight in C57Bl/6J mice. Male mice, age 9 weeks, were divided into three groups (ten mice per group) receiving modified high-fat (60 % of energy) diets. Two groups received a high-Ca diet (1·8 % calcium carbonate (CaCO3)), with casein or whey protein (18 % of energy), and one group received a low-Ca diet (0·4 % CaCO3) with casein for 21 weeks. Food intake was measured daily and body weight twice per week. Body fat content (by dual-energy X-ray absorptiometry) of all mice and faecal Ca and fat excretion of seven mice/group were measured twice during the study. Final body weight (44·1 (sem 1·1) g) and body fat content (41·6 (sem 0·6) %) were significantly lower (P < 0·05) in the high-Ca whey group than in the low-Ca casein group (48·1 (sem 0·8) g and 44·9 (sem 0·8) %). Body weight and body fat content of the high-Ca casein group did not differ significantly from the low-Ca casein group even though serum 1,25(OH)2-D3 levels were significantly lower (P < 0·001) in both high-Ca groups than in the low-Ca casein group. Thus changes in serum 1,25(OH)2-D3 do not seem to affect body weight in this animal model. There was a significant difference in fat excretion between the high-Ca whey and low-Ca casein groups (3·9 (sem 0·9) % in the high-Ca whey v. 1·4 (sem 0·2) % in the low-Ca casein group; P < 0·05), which may partly explain the effect on body weight.

Detection of QTL for body weight and body fat content in mice using genetic markers

1996 ◽  
Vol 113 (1-6) ◽  
pp. 373-379 ◽  
Author(s):  
G. Brockmann ◽  
D. Timtchenko ◽  
P. Das ◽  
U. Renne ◽  
G. Freyer ◽  
...  
Keyword(s):  
Body Weight ◽  
Genetic Markers ◽  
Body Fat ◽  
Fat Content ◽  
Body Fat Content
Sign in / Sign up

Export Citation Format

Share Document